bioSeedin’s Post

Biogen and Neomorph, Inc. have entered a research partnership aimed at discovering and developing molecular glue degraders for the treatment of Alzheimer’s disease and other neurological and immunological conditions. Neomorph CEO, co-founder and president Phil Chamberlain stated: “Neomorph’s molecular glue degrader platform represents a unique approach to drug discovery. We are excited to partner with Biogen, a leader in Alzheimer’s, rare and immunological diseases, to explore the potential of our technology in addressing some of the most challenging and valuable targets in these fields.” Biogen research head Jane Grogan stated: “As part of our modality agnostic research strategy, Biogen is committed to investing in new approaches to unlock biological targets that have remained difficult to reach. This collaboration with Neomorph reflects the approach we want to take to pair our internal drug development expertise with cutting-edge external innovation to create clinically meaningful therapies for patients.” Click here for the full article - https://lnkd.in/dbEWzp7a #pharma #molecularglue #neurology #immunology #alzheimers #biopharma #biotech

🌟 𝐈𝐧𝐌𝐞𝐝'𝐬 𝐈𝐍𝐌-𝟗𝟎𝟏: 𝐀 𝐍𝐞𝐰 𝐇𝐨𝐩𝐞 𝐟𝐨𝐫 𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫’𝐬 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭! 💡 𝗜𝗻 𝗝𝘂𝗹𝘆 𝟮𝟬𝟮𝟰, InMed Pharmaceuticals recently released preclinical data indicating its proprietary, #smallmolecule compound, INM-901, targets multiple #biological pathways associated with #Alzheimer’sdisease. Among the most interesting data from the recent reports, was the ability of its compound to extend the length of #neurites, which may indicate enhanced neuronal functioning in the #brain and the potential to reverse the #damage caused by Alzheimer’s disease. The company was encouraged with these breakthrough preclinical results and will be advancing the development of the INM-901 Alzheimer’s disease program. InMed's preclinical model of Alzheimer's disease, which is well characterised, showed encouraging outcomes in both in vitro and in vivo trials. The study claims that it might encourage neurite growth and extension, or neutogenesis, a crucial aspect of cell-to-cell communication. In in-vivo experiments, INM-901 also revealed decreased neuroinflammation and improved behaviour, memory, and cognitive function. 𝗕𝗿𝗼𝘄𝘀𝗲 𝗮𝘁 𝗼𝘂𝗿 𝗥𝗲𝗹𝗮𝘁𝗲𝗱 𝗥𝗲𝗽𝗼𝗿𝘁 👉:https://bit.ly/46jbV2x #AlzheimersTreatment #InnovativeTherapy #AlzheimersResearch #MultiFactorialApproach #BreakthroughMedicine #NeuroScience #AlzheimersHope #prophecymarketinsights

🌐 🧠 Neuroscience News 🧠 🌐 💷 LoQus23 Therapeutics Ltd announces £35m Series A financing to advance its small molecule somatic expansion inhibition therapy for Huntington's disease. "This financing will enable us to develop key clinical data to support the development of our exciting lead programme." David Reynolds - CEO ✅ US approves Karuna Therapeutics / Bristol Myers Squibb schizophrenia drug #Cobenfy with new mode of action. Congratulations to Daphne Zohar Bill Meury Steven Paul Steve Brannan and all those involved. 🤝 AstronauTx appoint Jane Rhodes as their CEO. "Jane has a strong track record of company formation, successful equity financing and forging large enabling Pharma partnerships, all of which will be invaluable in our next phase of growth." Tim Edwards - Chair 💶 BrainEver are looking to raise an additional €5m as part of a larger €35m Series B to launch clinical trials in 2025 to fight Charcot disease. Bernard GIlly ⏩ Ionis Pharmaceuticals, Inc. Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease. "With no approved treatments available for people living with AxD, receiving this Fast Track designation for zilganersen reflects the seriousness of this ultra-rare disease and the significant unmet need for treatment in this patient population" Eugene Schneider, Chief Clinical Development Officer #CNS #Neuroscience #Neurology

As CEO of Sinaptica Therapeutics, Ken is leading the team to advance their personalized closed-loop neuromodulation therapy for Alzheimer's, which has generated unprecedented Phase 2 sham-controlled clinical data that was recently published in Oxford journal, 'Brain.' Sinaptica has FDA Breakthrough status for its novel proprietary approach which combines rTMS, EEG, and Neuronavigation with a sophisticated ML-derived personalization engine based on a novel brain target-- the precuneus, the central hub of the Default Mode Network, a brain network involved in episodic memory. The company has completed all clinicals to date with non-dilutive funding, and is now in-process on a financing to complete the clinical product (SinaptiStim™️ ) and prepare to initiate a pivotal study in 2024. Previously to Sinaptica, Ken has 20+ years leading and growing new business ventures on both the 'Buy Side' and the 'Build Side.' He started his career in management consulting at Charles River Associates, then jumped to industry at CSL, then Baxter BioScience (now Takeda), and Boston Scientific, with leadership roles in marketing, strategy, and corporate development. At Boston Scientific's nearly $1B Neuromodulation division, he was the global commercial lead for the highly successful Cosman RF ablation business he helped acquire. He also built the division’s Strategy function, providing leadership in areas including strategic planning, BD assessment, R&D portfolio management, digital strategy, and investments in next-gen platforms & new indications. Meet Ken Mariash @ #Sachs_NIF More Info @ https://lnkd.in/dHgcp4fq #Neuroscience #Neurotech #NeurologyInnovation #BrainHealth #CNSDisorders #NeurologicalDiseases #ADPD #Neuropsychiatry #PsychedelicResearch #NeuroTechInvestment #Biotech #MedicalInnovation #NeuroscienceForum #NeuroInvestment #NextGenMedicine #NeuroscienceResearch #MentalHealthInnovation #BiotechIndustry

🌟🧬 Innovation in CIPN Treatment with #Neurolieve Biosciences 🧬🌟 #Neurolieve Biosciences is advancing a groundbreaking solution with its novel preclinical candidate drug for the treatment of Chemotherapy-Induced Peripheral Neuropathy (CIPN), addressing both symptoms and the underlying disease mechanisms. 🔬 Fc13-GalR2 is a fusion protein that acts as an agonist at Galanin Receptor 2 (GalR2). Preclinical evidence highlights that GalR2 agonism effectively modulates pain. Previous studies have demonstrated Fc13-GalR2's effectiveness in animal models of neuropathic pain. Additional studies to further validate Fc13-GalR2's effectiveness in CIPN animal models are currently in the design stage. 🔍 What makes Fc13-GalR2 promising? - It modulates potent chemokines and cytokines in macrophages during inflammatory processes. - It protects nerve cells from oxidative stress via the pERK1/2 signalling pathway. - Potential role in nerve regeneration following injury. 🔬 #Neurolieve Biosciences’ Plan: #Neurolieve Biosciences’ preclinical and clinical development plan includes validation of all the aforementioned mechanisms and hypotheses. This could lead to a drug capable of treating both the symptoms and physiological causes of a disease with vast unmet needs. #Neurology #HealthcareInnovation #CIPN #ClinicalResearch #PainManagement #Biotechnology #Neurolieve #HealthAndInnovation

Very excited about this collaboration with the PSPP! At Goldenrod Therapeutics, we are developing next-generation, small molecule, oral PDE4B inhibitors for the treatment of severely debilitating diseases that affect the central nervous system and for which current treatments are either inadequate or non-existent. Globally, about 1 in 5 people suffer from chronic pain, an extremely complex and debilitating condition which varies significantly between individuals. Unfortunately, highly addictive opioids are still the most commonly prescribed medications for chronic pain and, despite decades of effort, there are still no exceptional alternatives on the market. Goldenrod's non-opioid small molecule drugs have the potential to change this! Importantly, this partnership marks our second collaboration with an NIH Institutional Program - the first being our acceptance into NIDA's Addiction Treatment Discovery Program (ATDP) in 2022. We are thrilled to work with these key partners, among others, to advance Goldenrod's promising new treatments forward and to address the unmet needs of patients worldwide. #chronicpain #painresearch #paintherapeutics

🧬 in Precision Medicine: Arialys Therapeutics Emerges with $58M to Transform Neuropsychiatric Treatment TL;DR: • Launches with $58M from top investors including J&J • Developing ART5803 for anti-NMDA receptor encephalitis • Plans FDA submission for clinical trials in 2024 • Exploring applications for schizophrenia and Alzheimer's Arialys Therapeutics is pioneering an immune system-focused approach to neuropsychiatric disorders, mirroring successful precision oncology strategies. Their lead candidate, ART5803 (acquired from Astellas Pharma), shows promising preclinical results in treating brain inflammation and behavioral symptoms. Backed by industry giants including Avalon BioVentures, MPM BioImpact, and J&J's venture arm, Arialys joins a resurgent neuroscience field that's seeing renewed interest from major pharma companies. This development follows recent momentum in neuroscience, with Neumora Therapeutics' $600M+ funding and upcoming IPO, plus GSK's renewed commitment to brain disease research. 💡 What are your thoughts on the intersection of immunology and neuropsychiatry? Share your insights on this emerging therapeutic approach. #Biotech #PrecisionMedicine #Neuroscience #BiotechInnovation #DrugDevelopment #intelligencesimplified #pharma #biotech #biodatastudio

April marks International #ParkinsonsAwarenessMonth, a time to educate and empower communities about this neurological disorder. From Ncardia, we work hard to provide predictive iPSC-based models and assays to drug innovators in the field of Parkinson's disease and other neurodegenerative diseases. If you are fighting against Parkinson's disease drivers like protein aggregation or neuroinflammation, check out this poster. https://lnkd.in/eTwzG69f Three in vitro assays based on hiPSC-derived neurons to screen the effect of drug candidates on the aggregation of α-synuclein, Tau and TDP-43. Together, let's make a difference! #ABCsOfPD #neuroscience #drugdiscovery #Ncardia #Empowerment

𝗡𝗲𝘂𝗿𝗼𝗹𝗼𝗴𝘆 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹 𝗠𝗮𝗿𝗸𝗲𝘁 𝟮𝟬𝟮𝟰-𝟮𝟬𝟯𝟬. 𝗚𝗹𝗼𝗯𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗦𝗮𝗺𝗽𝗹𝗲 𝗣𝗗𝗙: https://lnkd.in/dy8zKJWr The report offers an in-depth exploration of the Neurology Clinical Trial industry chain, covering market dynamics and key enterprises in both developed and developing markets, with a focus on Neurodegenerative Disorders, Cardiovascular Disorders, and cutting-edge technologies. It delves into the market status, patent landscape, and emerging applications while analyzing regional markets, highlighting steady growth in North America and Europe propelled by government support and rising awareness. Meanwhile, Asia-Pacific, led by China, dominates the global market due to strong domestic demand, favorable policies, and robust manufacturing capabilities, providing a comprehensive understanding of the Neurology Clinical Trial sector with insights into its components, stakeholders, and prevailing trends, challenges, and opportunities. 𝗧𝗼 𝗞𝗻𝗼𝘄 𝗗𝗲𝗺𝗮𝗻𝗱 𝗼𝗳 𝗡𝗲𝘂𝗿𝗼𝗹𝗼𝗴𝘆 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹 𝗠𝗮𝗿𝗸𝗲𝘁. 𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗦𝗮𝗺𝗽𝗹𝗲 𝗣𝗗𝗙: https://lnkd.in/dy8zKJWr *𝗕𝘆 𝗧𝘆𝗽𝗲: Bone Marrow, Epidermis, Mesenchymal Stem Cells, Haematopoietic Stem Cells, Chondrocytes *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Neurodegenerative Disorders, Cardiovascular Disorders, Orthopedics, Wound Healing, Other *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻: North America, Europe, Asia-Pacific, South America, Middle East & Africa *𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Brainstorm Cell Therapeutics, Opexa Therapeutics, U.S. Stem Cell, Inc, Lonza, Bristol Myers Squibb, Vericel® Corporation, Catalent Pharma Solutions, Lineage Cell Therapeutics, Castle Creek Biosciences, Inc., Sangamo Therapeutics, Inc., Novarti, Holostem S.r.l., Pharmicell Co.,Ltd., Autolus Therapeutics, Bayer, Sartorius, Daiichi Sankyo US, Takeda, Sumitomo Corporation #NeurologyResearch #ClinicalTrialUpdates #NeuroscienceTrials #BrainHealthStudies #ClinicalResearch #NeurologyInnovation #TrialResults #NeurologyAdvancements #PatientCare #ResearchBreakthroughs

Exciting progress in Alzheimer's research! Our new study published in Alzheimer's & Dementia (https://lnkd.in/eNGmMJKp) demonstrates that a novel small molecule ligand improves memory and brain function in aged Alzheimer's mice. This approach, targeting TrkB/C receptors, strengthens neuronal communication, promotes activity-dependent protein expression and activation and regulates activity-dependent transcriptomic immune response, offering promise for future treatments. Huge thanks to all the authors for their efforts and collaboration! What do you think about this new approach? #AlzheimersResearch #NeuroScience